Physician profile
Michal Phillips
NPI 1659497311
$6,212.68
in general payments reported to CMS, 2019-2025
29 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.94 · 2021: $16.59 · 2022: $769 · 2023: $1,946 · 2024: $1,721 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,415.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $716.70 | 2022-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $707.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $679.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $570.13 | 2022-2025 | |
| Novo Nordisk INC | $532.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $530.91 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $451.72 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $399.72 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $284.70 | 2022-2025 | |
| Mylan Specialty L.P. | $203.02 | 2022-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.09 | 2023-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $150.67 | 2022-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $149.96 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $96.04 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.56 | 2022-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $71.63 | 2022 | |
| Dexcom, INC. | $69.58 | 2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $66.37 | 2024-2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $57.86 | 2022-2023 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $40.98 | 2023-2025 | Livalo, Zoryve |
| Inspire Medical Systems, INC. | $37.42 | 2025 | Inspire |
| Ironshore Pharmaceuticals INC. | $25.11 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $21.08 | 2024 | Imcivree |
| Biogen, INC. | $18.94 | 2025 | Skyclarys |
| Averitas Pharma INC. | $18.02 | 2025 | Qutenza |
| Amarin Pharma, INC. | $16.59 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $14.48 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $14.25 | 2023 | |
| Lundbeck LLC | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michal Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.